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Background: The age-related weakening of the immune system makes elderly subjects less responsive to influenza
vaccination. In the last years, two “enhanced vaccines” were licensed for individuals aged ≥65 years, one being a
subunit vaccine (Fluad®) containing the MF59 adjuvant administered intramuscularly (IM-MF59) and the other one a
split non-adjuvanted vaccine administered intradermally (Intanza® 15mcg) (ID). In the present study, we evaluated
and compared the antibody responses against the three vaccine antigens and heterovariant A(H3N2) circulating
viruses induced by IM-MF59 and ID influenza vaccines in 80 elderly institutionalized volunteers (40 per group)
during the Winter season 2011–2012.
Results: Hemagglutination inhibiting (HI) antibody titers were assessed in blood samples collected before, 1 and
6 months after vaccination. One month after vaccination both the IM-MF59 and ID vaccines induced increases in HI
titers against all the three vaccine strains. The results in the two groups were similar against the A(H3N2) and
A(H1N1) strains. Responses against the B strain typically tended to be higher after ID than IM-MF59, yet both
vaccines stimulated lower responses against the B strain than against the two A strains. The two vaccines induced
favorable results also against four epidemic drifted A(H3N2) viruses circulating in Winter 2011–2012. Six months
after vaccination, the HI titers decreased in both groups.
Conclusion: The responses induced by IM-MF59 and ID vaccines in institutionalized elderly people were similar
against the A(H3N2) and A(H1N1) strains but frequently higher, for the ID, against the B strain. The two vaccines
induced positive responses against drifted A(H3N2) circulating viruses.
Keywords: MF59-adjuvanted influenza vaccine, Intradermal influenza vaccine, Homologous and heterologous antibodiesBackground
Vaccination is the primary means of preventing seasonal in-
fluenza infection. However, although it can effectively pre-
vent influenza and its complication in healthy adults, the
age-related weakening of the immune system (immunose-
nescence) makes elderly subjects not only more susceptible
to infection, but also less responsive to vaccination [1-4].* Correspondence: annaiorio42@gmail.com
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unless otherwise stated.To meet the challenge of improving vaccine efficacy in the
elderly and in other influenza risk groups, several strat-
egies have been pursued [5]. Some of these research ap-
proaches have led to the licensure of new “enhanced
vaccines” and two of these were specially licensed for indi-
viduals aged ≥65 years. The first one was a subunit vac-
cine containing the MF59 adjuvant (Fluad®) with the
aim to increase vaccine immunogenicity, to be adminis-
tered intramuscularly (IM-MF59) [6]. The second vac-
cine was a split non-adjuvanted vaccine administered
intradermally (Intanza®) (ID), supposed to reach theal Ltd. This is an Open Access article distributed under the terms of the Creative
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immune-rich environment of the dermis [7]. In most in-
stances, both vaccines were found to be capable of indu-
cing higher, or comparable, immune responses in the
elderly when compared to conventional non-enhanced in-
fluenza vaccines [8-12]. Moreover, since mismatches be-
tween the vaccine strains and the circulating viruses can
cause an additional reduction in vaccine efficacy [13], the
two vaccines were also investigated, with favorable results,
for their ability to induce antibody in the elderly not only
against the vaccine strains, but also against heterovariant
influenza strains [14]. The aim of our study was to evalu-
ate and directly compare the ability of the two licensed en-
hanced vaccines to elicit an antibody response against the
vaccine antigens. Moreover, we studied the long-term im-
munogenicity and the cross-responses against circulating
mismatched influenza A(H3N2) viruses. The volunteers
were institutionalized elderly people and the period of ob-
servation was the 2011–2012 Winter season.Results
Characteristics of the study subjects
The study included a total of 80 elderly subjects living in
two nursing homes located in Umbria, a region of central
Italy, (42 at the “Opera Pia Bartolomei-Castori” and 38 at
the “Casa Serena” nursing homes). Forty volunteers were
vaccinated with IM-MF59 and 40 with ID influenza vaccine
commercially available for the 2011–2012 Winter season.
As reported in Table 1, the baseline characteristics of
the two groups were similar and for this reason the re-
sults obtained with the two vaccines could be compared.Table 1 Baseline characteristics of elderly
institutionalized subjects participating in the study
IM-MF59 (N. 40) ID (N. 40) p value
% Female 87.5 82.5 0.745




% Underlying disease** 100 100 1.000
% Cardiovascular diseases 42.5 38.7 0.747
% Diabetes 15.0 22.6 0.413
% Cancer 5.0 0.0 0.589
% Other chronic diseases 97.5 93.5 0.412
% Chronic use of drugs*** 92.5 100 0.119
*calculated as percentages of vaccinated people considering the 71 subjects
with available data for previous vaccinations.
**it was possible for each subject to have more than one disease.
***drugs most frequently used were antihypertensive/inotropic drugs
and benzodiazepines.Immunogenicity of 2011–2012 IM-MF59 and ID influenza
vaccines: hemagglutination inhibiting (HI) antibody
response to the three vaccine antigens and persistence
Vaccine immunogenicity was evaluated by comparing HI ti-
ters in blood samples collected before and 30 days after
vaccination and persistence of immune response by consid-
ering titers at 6 months of vaccination. The results are re-
ported as protection rate (numbers of volunteers showing
HI titers ≥40, considered to be associated with protection
from influenza infection [15]), geometric mean titers
(GMT), mean fold increase (MFI) of GMT (ratio of post-
immunization to pre-immunization titers), seroconversion
rate (subjects with a fourfold or greater increase in titer in
pre-vaccination seropositive subjects or from <10 to ≥40 in
seronegative volunteers).
As reported in Table 2, the pre-vaccination seroprotec-
tion rate and the values of GMT were similar in the IM-
MF59 and ID groups and a significant increase in these
values was observed 1 month after vaccination in both
vaccine groups against the A(H3N2) and A(H1N1) vaccine
components. The increases against the B vaccine antigen
were not significant, except for GMT values in the ID
group. HI titers at 6 months of vaccination decreased, as
compared with those found at 1 month in both groups.
No significant differences were observed across vaccine
groups against the A(H3N2) and A(H1N1) vaccine antigens
1 and 6 months after vaccination. On the contrary, serocover-
sion rates against the B antigen were higher, both at 1 (40.0%
vs. 10.0%, p < 0.01) and 6 (17.5% vs. 0.0%, p < 0.01) months,
in the ID group as compared with the IM-MF59 group.
The serological results observed 1 month post vaccin-
ation were also evaluated according to the Committee for
Medicinal Products for Human Use (CHMP) criteria for
approval of influenza vaccines in the elderly, which require
that at least one of the following criteria must be met, pro-
tection rate ≥60%, MFI of GMT ≥2 and seroconversion rate
≥30% [16]. Although the pre-requisite of at least 50 persons
per group was not met (the two groups examined were of
only 40 people) and although there are some controversies
on the identification of a single threshold (HI titer ≥40) for
defining protection [17], all three CHMP criteria were met
by both vaccines against A(H3N2) and A(H1N1) viruses
and by ID vaccine against the B virus. IM-MF59 vaccine
failed MFI and seroconversion criteria against B virus.
In order to have more comparable data, post-vaccination
GMT values were adjusted for pre-vaccination status
(Figure 1), as suggested by Beyer et al. [18]. One month after
vaccination not only, as previously found, the responses
against B virus (3.0 vs. 0.8, p < 0.01), but also against A
(H3N2) virus (3.2 vs. 2.4, p < 0.05) were significantly higher
in the ID group as compared with the IM-MF59 group.
Six months after vaccination statistically higher values
were found in the ID group against A(H1N1) (1.3 vs. 0.7,
p < 0.01) and B (1.9 vs. 0.0, p < 0.01) viruses.
Table 2 HI antibody response against the three 2011-2012 influenza vaccine antigens 1 and 6 months after IM-MF59 or ID vaccination
Vaccine component Group (N)
Seroprotection rate (%) GMT MFI Seroconversion rate (%)
[95% C.I.] [95% C.I.] [95% C.I.] [95% C.I.]
Pre-vacc. 1 month 6 months Pre-vacc. 1 month 6 months 1 month 6 months 1 month 6 months
A/Perth/16/09 (H3N2)
IM-MF59 50.0 87.5** 66.5 25.5 83.7** 53.8* 3.3 2.1 47.5 17.5
(40) [37.3-62.6] [76.4-93.8] [52.0-76.1] [16.3-40.1] [44.8-156.2] [27.3-106.2] [1.9-5.7] [1.1-4.1] [35.1-60.2] [9.8-29.4]
ID 50.0 92.5** 67.5 28.3 131.3** 69.1 4.6 2.4 60.0 30.0
(40) [37.3-62.6] [82.6-97.0] [54.5-78.2] [14.7-54.5] [72.3-238.5] [33.2-144.0] [2.8-7.8] [1.3-4.4] [47.0-71.7] [19.6-42.9]
A/California/7/09 (H1N1)
IM-MF59 25.0 72.5** 40.0 15.0 55.0** 22.0 3.7 1.5 50.0 7.5
(40) [15.5-37.6] [59.7-82.4] [28.3-53.0] [9.2-24.5] [31.9-94.8] [13.0-37.3] [2.4-5.6] [1.1-2.0] [37.3-62.6] [3.0-17.4]
ID 32.5 70.0** 50.0 15.8 61.0** 29.7 3.8 1.9 42.5 17.5
(40) [21.7-45.5] [57.1-80.3] [37.3-62.6] [9.0-28.0] [31.4-118.4] [17.0-52.5] [2.2-6.8] [1.2-2.8] [30.5-55.5] [9.8-29.4]
B/Brisbane/60/08
IM-MF59 55.0 75.0 57.5 31.5 50.8 31.5 1.6 1.0 10.0 0.0
(40) [42.1-67.2] [62.4-84.4] [44.5 -69.5] [18.8–52.7] [29.6-87.0] [18.5-53.5] [1.3-2.0] [0.9-1.1] [4.6-20.5] [0.0-6.3]
ID 40.0 75.0 60.0 20.0 62.9* 35.9 3.2 1.8 40.0 $$ 17.5 $$
(40) [28.3-53.0] [62.4-84.4] [47.0-71.7] [12.7-32.0] [35.6-114.7] [20.7-62.2] [1.7-6.0] [1.0-3.1] [28.3-53.0] [9.8-29.4]
*p < 0.05 and **p < 0.01 comparing pre and post-vaccination data.






























































Figure 1 One and 6 months post-vaccination GMT against the three 2011-12 influenza vaccine components adjusted according to
pre-vaccination titers. $: p < 0.05; $$: p < 0.01 comparing the two vaccine groups.
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induced by IM-MF59 and ID influenza vaccines against
epidemic drifted A(H3N2) viruses circulating in the
2011–2012 Winter season
During the 2011–2012 Winter season in our laboratory,
the regional reference laboratory for Umbria of INFLU-
NET (Italian Surveillance Influenza Network), a total of
61 influenza viruses were identified on examining 91
throat swabs by cultivation in Madin-Darby canine kidney
(MDCK) cells and/or Real-Time Reverse-Transcriptase-
Polymerase-Chain-Reaction (RT-PCR). Swabs were col-
lected from people with influenza-like illness (ILI) living in
the area where the two nursing homes were located. Most
of the viruses isolated not only in Umbria (53/61, i.e. 87%),
but also in other parts of Italy, were A(H3N2) viruses, pre-
senting antigenic and genetic patterns different from the
A(H3N2) component of the 2011–2012 influenza vaccine
[19]. The results obtained analyzing the nucleotide se-
quence of the HA1 domain of the hemagglutinin (HA)
gene of a selected number of these A(H3N2) viruses,
encompassing four viruses isolated in Umbria, are re-
ported in Figure 2. The data show a high genetic affinity
of these four viruses with the recent circulating viruses be-
longing in the A/Victoria/208/2009 clade, different from
the clade of the 2011–2012 A(H3N2) vaccine component
(A/Perth/16/2009 clade). Because of the importance of
documenting the ability of the influenza vaccine to induce
heterologous immune responses, we examined the induc-
tion of HI antibody responses against those four drifted A
(H3N2) viruses following immunization with the two dif-
ferent enhanced 2011–2012 influenza vaccines. The re-
sults obtained, as reported in Table 3, show that, in most
instances, pre-vaccination titers were comparable in the
two vaccinated groups (except for seroprotection rate in
the ID group, higher than in the IM-MF59 group against
A/Perugia/44/12, p < 0.05) and in the same range as those
found against the vaccine A(H3N2) virus (Table 2). Sero-
protection rates ranged between 25.0% and 65.0%, as com-
pared to 50.0% and 50.0% and GMT values ranged,indeed, between 15.4 and 33.7, as compared with 25.5 and
28.3 against A(H3N2) vaccine antigen. One month after
vaccination, significant increases were observed both in
seroprotection and in GMT values, with the exception of
seroprotection rate against the A/Perugia/06/12 virus. On
comparing the two vaccinated groups, significantly higher
values were found in the ID group as compared with the
IM-MF59 group against A/Perugia/20/12 and A/Perugia/
44/12 viruses if considering the values of seroprotection
(72.5% vs. 47.5%, p < 0.05, 87.5% vs. 67.5% p < 0.05, respect-
ively, Table 3) and against A/Perugia/06/12 on considering
the values of GMT corrected for pre-vaccination status (2.5
vs. 1.9, p < 0.01, Table 3). Moreover, the post-vaccination
values tended to be lower as compared to those observed
against the A(H3N2) vaccine component. On comparing
circulating (Table 3) with vaccine A(H3N2) (Table 2) vi-
ruses, the GMT values ranged, respectively, from 35.4 to
75.9 and from 83.7 to 131.3, the MFI of GMT from 2.0 to
2.5 and from 3.3 to 4.6, and the percentage of seroconver-
sions from 17.5% to 37.5% and from 47.5% to 60.0%.
As reported in Table 3, of the three CHMP criteria, the
seroprotection rate and the MFI of GMT were always met,
with the exception of the seroprotection rate against A/
Perugia/20/12 antigen (47.5%) after IM-MF59. The sero-
conversion rate was in most instances lower than 30.0%, ex-
cept for IM-MF59 group against A/Perugia/44/12 (37.5%)
and for ID group against A/Perugia/06/12 (35.0%).
Discussion
This study describes the immunogenicity and the ability to
prevent influenza infection of two seasonal trivalent influ-
enza enhanced vaccines, commercially available during
Winter 2011–2012, characterized by the prevalent circula-
tion of drifted A(H3N2) influenza viruses. The two vac-
cines, Fluad® and Intanza® 15mcg, meant to address the
challenge of immunosenescence using different approaches
(MF59 adjuvant and intradermal route of administration)
were administered to 80 elderly volunteers (40 for vaccine
group) living in two nursing homes.
a 
A/Brisbane/10/2007: vaccine strain 09/10
b 
A/Perth/16/2009 : vaccine strain 10/11-11/12 
c 







































Figure 2 (See legend on next page.)
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Figure 2 Phylogenetic analysis of drifted A (H3N2) viruses circulating in the 2011–2012 winter. The phylogenetic tree represents the
analysis of the HA1 nucleotide sequences of the HA gene of different influenza A(H3N2) viruses isolated in Italy in the Winter season 2011–2012.
The four epidemic drifted A(H3N2) viruses isolated in Umbria (A/Perugia/06/12; A/Perugia/20/12; A/Perugia/44/12; A/Perugia/50/12) were used as
antigens for studying heterologous antibody responses induced by IM-MF59 and ID influenza vaccine.
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three vaccine antigens (Table 2), are in accordance with
previous reports demonstrating the ability of the two po-
tentiated vaccines, IM-MF59 [8,12] and ID [9-12], to elicit
antibody responses in elderly volunteers. One month after
vaccination significant increases in HI antibody titers were
observed against A(H3N2) and A(H1N1) vaccine strains,
whereas the responses against the B vaccine antigen, as
previously reported for traditional inactivated [20,21] and
potentiated [9,22] influenza vaccines, were more limited.
A direct comparison of the HI antibody responses in-
duced by the same two potentiated vaccines (IM-MF59
and ID) in elderly people was previously reported by Van
Damme [23] for the 2007–2008 Winter and by Scheifele
et al. [12] for the 2011–2012 Winter season, the same as
the one we examined. Since Van Damme et al. [23] re-
ported the seroprotection and seroconversion data as a
figure, only GMT values and the fulfillment of CHMP pa-
rameters could be compared. The results of Van Damme
et al. [23] and of Scheifele et al. [12] differ under someTable 3 HI antibody response against four drifted epidemic A
Perugia/20/12; A/Perugia/44/12; A/Perugia/50/12) after IM-MF
Epidemic virus Group(N.)
Seroprotection rate (%) GMT
[95% C.I.] [95% C
Pre-vacc. 1 month Pre-vacc. 1
A/Perugia/06/12
IM-MF59 32.5 70.0** 20.7
(40) [21.7-45.5] [57.1-80.3] [14.4-29.7] [3
ID 45.0 82.5 24.2
(40) [32.8-57.9] [70.6-90.2] [16.7-35.0] [4
A/Perugia/20/12
IM-MF59 25.0 47.5* 15.4
(40) [15.6-37.6] [35.1-60.3] [10.0-24.1] [2
ID 37.5 72.5**$ 18.0
(40) [26.1-50.5] [59.7-82.4] [12.1-26.9] [2
A/Perugia/44/12
IM-MF59 32.5 67.5** 20.0
(40) [21.7-45.5] [54.5-78.3] [13.2-30.3] [3
ID 55.0 $ 87.5**$ 28.3
(40) [42.1-67.2] [76.4-93.8] [18.6-42.9] [4
A/Perugia/50/12
IM-MF59 50.0 82.5** 26.9
(40) [37.4-72.6] [70.6-90.2] [16.9-42.7] [4
ID 65.0 90.0** 33.7
(40) [52.0-76.1] [79.5-59.4] [21.2-53.4] [5
*p < 0.05 and **p < 0.01 comparing pre and post-vaccination data.
$p < 0.05 $$p < 0.01 comparing the two vaccine groups.
#post-vaccination GMT values corrected for pre-vaccination status.respects from ours. Considering the responses against the
two A vaccine strains, post-vaccination GMT titers against
the A(H3N2) strain were higher in the IM-MF59 as com-
pared with the ID group both in Van Damme et al. [23]
and Scheifele et al. [12], whereas our data did not evidence
differences (Table 2). Indeed we found that the GMT cor-
rected for pre-vaccination status were even higher in the
ID vs. IM-MF59 group (Figure 2). In accordance with Van
Damme et al. [23] we observed similar responses against
the A(H1N1) strain, whereas Scheifele et al. [12] found
higher post-vaccination GMT titers in volunteers vacci-
nated with IM-MF59 as compared with ID group. How-
ever the differences, although statistically significant, were
marginal and the three CHMP requirements were always
reached against the two A vaccine strains [12].
Examining the post-vaccination GMT values against the
B strain, the results obtained by Scheifele et al. [12] could
not be evaluated because of the high baseline antibody
values precluding meaningful response assessment. Simi-
lar post-vaccination GMT were reported by Van Damme(H3N2) viruses circulating in Umbria (A/Perugia/06/12; A/
59 or ID influenza vaccine
MFI GMT corrected # Seroconversion rate (%)
.I.] [95% C.I.] [95% C.I.] [95% C.I.]
month 1 month 1 month 1 month
43.6** 2.1 1.9 27.5
0.8-61.8] [1.5-2.9] [1.4-2.4] [17.6-40.3]
58.6* 2.4 2.5$$ 35.0
1.1-83.5] [1.7-3.5] [1.6-3.1] [23.9-48.0]
35.4** 2.3 1.9 25.0
3.3-53.3] [1.6-3.4] [1.0-2.4] [15.6-37.6]
38.0** 2.1 1.9 17.5
6.6-54.3] [1.5-3.0] [1.4-2.4] [9.8-29.4]
50.1** 2.5 2.1 37.5
2.0-78.5] [1.7-3.8] [1.2-3.0] [26.1-50.5]
56.6** 2.0 2.6 25.0
1.2-77.6] [1.4-2.9] [2.0-3.0] [15.6-37.6]
61.7** 2.3 2.6 25.0
2.1-90.3] [1.5-3.5] [1.7-3.1] [15.6-37.6]
75.9** 2.3 2.4 20.0
0.6-113.9] [1.5-3.3] [1.8-2.8] [11.6-32.2]
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evidenced a tendency for a higher immunogenicity in the
ID group compared with IM-MF59, especially after GMT
adjustment for pre-vaccination titers (Figure 2). Only one
CHMP requirement was reached in the two vaccine
groups examined by Van Damme et al. [23] and in our
IM-MF59 group, whereas all three requirements were met
in our ID group.
Many different explanations can account for these dif-
ferences. All the volunteers examined were 65 years or
more, however the mean age of our population was higher
(over 80 years) as compared with the mean age of the
other two studies (lower than 80 years). We examined
prevalently frail elderly people living in nursing homes,
whereas volunteers studied by Scheifele et al. [12] were in
most instances not frail and not living in care facilities.
Moreover, the number of volunteers we studied was very
limited (80 people) as compared with Van Damme et al.
(795 participants) [23] and Scheifele et al. (911 partici-
pants) [12].
The potential variability in the immunogenicity of the
injected influenza strains might have influenced the results
obtained since all the three antigenic strains of the 2011–
2012 Winter season, studied by us and Scheifele et al. [12],
were updated as compared with those of 2007–2008 vac-
cine examined by Van Damme et al. [23]. Previous contact
with influenza virus due to natural infection or vaccination
might also be considered. A high percentage of the people
of the three trials received influenza vaccine in the previ-
ous years. However, the very high antibody titers against
the B strain found by Scheifele et al. [12], seem to suggest
a possible different natural circulation of influenza viruses
in the countries where the three studies were performed.
Moreover, the possible contribution of the use of ether-
treated B virus in the HI tests performed by Scheifele et al.
[12] needs to be considered.
The other aspect examined by us and by Scheifele et al.
[12] was the persistence of the vaccine induced antibody
responses in the longer term, i.e. 6 months after vaccin-
ation. In accordance with Scheifele et al. [12] we found
that HI antibody titers decreased against all the three vac-
cine strains in both vaccine groups 6 months after vaccin-
ation (Table 2); the HI titers evaluated by Scheifele et al.
[12] as seroprotection against the two A strains did not
differ between the two vaccine groups in contrast with the
results observed shortly after vaccination. Our results evi-
denced that the responses found in people vaccinated with
ID vaccine tended to be slightly higher as compared with
IM-MF59 group especially if MFI of GMT and serocon-
versions rates are taken in account.
Further considerations derive from the data obtained
on investigating the ability of the two vaccines to induce
cross-reactive antibodies against four epidemic A(H3N2)
strains circulating in the Winter 2011–2012 and foundto be closely genetically correlated to the A/Victoria/208/
2009 clade, different from the A/Perth/16/2009 clade (vac-
cine strain) (Figure 2). For the first time, the two potenti-
ated vaccines were directly compared and the results
confirm previous data demonstrating the ability of MF59-
adjuvanted and intradermal vaccines [14] to elicit cross-
reactive antibodies against heterologous or circulating
viruses in elderly people. Both IM-MF59 and ID vaccines
induced favorable immune responses against the four A
(H3N2) circulating influenza viruses examined and at least
two (seroprotection rate and MFI of GMT) of the CHMP
criteria were met (Table 3). No substantial differences
were found between the two vaccine groups, although HI
titers were somewhat higher in the ID group. However,
the post-vaccination values against the four circulating vi-
ruses were substantially poorer than those against the
homologous A(H3N2) virus. In accordance with these re-
sults, suggesting that the drifted circulating strains exam-
ined may have different antigenic patterns with possible
impact on vaccine immunogenicity, the A/Perth/16/2009
vaccine strain was replaced for the 2012–2013 Winter by
A/Victoria/361/2011, belonging to the A/Victoria/208/
2009 clade [24].
Conclusions
In conclusion, this study, although limited in size, con-
firmed that the use of MF59 adjuvant and intradermal vac-
cination appear to be appropriate strategies to address the
challenge of declining immune responsiveness in the eld-
erly after influenza vaccination. Both IM-MF59 and ID in-
fluenza vaccines for the 2011–2012 Winter season were
found to induce significant antibody responses against the
three vaccine antigens, although the responses against the
B antigen and the persistence of antibodies 6 months after
vaccination tended to be higher in subjects vaccinated
with ID than in individuals receiving IM-MF59 vaccine.
Moreover, the two vaccines induced immune responses
against drifted circulating influenza A(H3N2) viruses, al-
though to a lesser extent as compared with A(H3N2) vac-
cine antigen.
Since a systematic meta-analysis for IM-MF59 versus ID
vaccine is not available, these results can be considered
preliminary, awaiting more extensive examination and sys-
tematic evidence.
Methods
Study population and vaccination
The study included a total of 80 elderly people living in two
nursing homes located in Umbria (Italy) immunized with a
single dose of trivalent influenza vaccine in November
2011. Two commercialized vaccines were freely offered for
the Winter season 2011–2012 by the Public Health Author-
ities of Umbria (Italy) to the high risk group of elderly
people: intramuscular MF59-adjuvanted (Fluad®, Novartis
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mcg, Sanofi-Pasteur MSD, France) (ID) influenza vaccine.
The two vaccines contained 15 mcg of A/Perth/16/09
(H3N2), A/California/7/09 (H1N1) and B/Brisbane/60/08,
respectively in 0.5 ml (IM-MF59) or 0.1 ml (ID). After
obtaining informed consent, subjects were randomly
assigned to receive in the deltoid region one dose of intra-
dermal Intanza® 15 mcg (ID) or of intramuscular Fluad®
(IM-MF59). Forty volunteers were immunized with IM-
MF59 and 40 with ID influenza vaccine. Serum samples
were examined for each volunteer before and approxi-
mately 1 and 6 months after vaccination. The study was
conducted in accordance with all relevant regulations and
with ethical standards set out in the Helsinki Declaration
and Good Practice Guidelines and since both vaccines were
assigned to the two nursing homes for the vaccination of
elderly residents within the annual influenza vaccination
campaign and sera were leftover sera from samples col-
lected for clinical routine controls, the study did not need
to be registered as a formal trial. Demographic, current
medical conditions, prescribed medications, and previous
influenza vaccination data were obtained from each subject
at the time of vaccination.
HI antibody assay and vaccine immunogenicity
Serum samples taken from the same subject and frozen at
−20°C were tested simultaneously for HI antibodies titers
against different influenza antigens. HI titers were deter-
mined by a standard microtiter method using 0.5% turkey
erythrocytes. All sera were treated with receptor-destroying
enzyme and heat-inactivated at 56°C for 30 min to remove
non-specific inhibitors [25]. To eliminate any subjective
bias, HI titers determinations were determined in a blind
fashion, i.e. with the tester unaware of which treatment the
donor had received.
Viruses
The antibody responses were evaluated against the three
egg-grown vaccine strains and against four circulating A
(H3N2) field viruses (A/Perugia/06/12, A/Perugia/20/12,
A/Perugia/44/12 and A/Perugia/50/12) isolated examining
throat swabs (by culturing in MDCK cells and by RT-
PCR) from people with ILI living in Umbria, Italy. Viruses
were genetically characterized by sequencing the complete
HA1 domain of the HA gene with specific primers (depos-
ited in Gisaid; A/Perugia/06/12 [EPI:438358], A/Perugia/
20/12 [EPI:438360], A/Perugia/44/12 [EPI:392313] and A/
Perugia/50/12 [EPI:392315]). PCR products were ampli-
fied as previously reported [26] and purified using QIA-
quick PCR purification kit (Qiagen). Nucleotide sequences
were obtained with the Big Dye Terminator Cycle Se-
quencing v1.1 ready Reaction kit using an ABI PRISM
310 sequencer (Applied Biosystems) and were aligned
by using ClustalW 105 program (EMBL-EBI, EuropeanBioinformatics Institute). Phylogenetic analysis was per-
formed by using version 3.1 of the MEGA software package
[27]. The Kimura-2-distance method and the Neighbor-
Joining algorithm were used for the phylogenetic tree
reconstruction.
Statistical analysis
Differences between groups and results obtained using vac-
cine and epidemic antigens were analyzed by Student’s t
test for continuous statistics (GMT), and by chi-square test
for qualitative statistics (protection, seroconversion rate and
clinical and demographic characteristics). HI titers were
also transformed into binary logarithms, corrected for pre-
vaccination status as described by Beyer et al. [18] and
expressed as median titers, with the corresponding 25–
75° inter-quartile range. Comparisons of corrected post-
vaccination titers were analyzed by Wilcoxon test.
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